Literature DB >> 978103

Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women.

G V Groom, K Griffiths.   

Abstract

Plasma levels of LH, FSH, prolactin, oestradiol and progesterone were determined daily during two consecutive menstrual cycles in six women volunteers. During the first (control) cycle no treatment was given and normal secretion of these hormones was observed. Oral administration of tamoxifen (20 mg/day), for either 5 or 10 days of the follicular phase of the second cycle, caused no change in either the overall length of the cycle or the time of occurrence of the mid-cycle gonadotrophin surge. There was little difference in the secretion of LH, FSH and progesterone during the control and test cycles. A two- to eight-fold increase in oestradiol levels was observed during test cycle which was most pronounced at the times of mid-cycle and mid-luteal hormone peaks. There was a significant decrease in plasma prolactin levels at mid-cycle but no real difference could be seen during the remainder of the cycle. The data suggest that tamoxifen may act directly on the ovary to stimulate oestradiol release without intermediary gonadotrophin stimulation. As the drug apparently inhibited prolactin secretion even in the presence of high oestradiol levels, an alternative explanation may be that the reduced prolactin concentration permits augmented ovarian stimulation by normal concentrations of gonadotrophins.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 978103     DOI: 10.1677/joe.0.0700421

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  26 in total

1.  Gynaecological effects of tamoxifen.

Authors:  S M Ismail
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

2.  Optimal systemic therapy for early breast cancer in women: a clinical practice guideline.

Authors:  A Eisen; G G Fletcher; S Gandhi; M Mates; O C Freedman; S F Dent; M E Trudeau
Journal:  Curr Oncol       Date:  2015-03       Impact factor: 3.677

Review 3.  Long-term adjuvant tamoxifen therapy for breast cancer.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1990-05       Impact factor: 4.872

4.  Comparison between tamoxifen and clomiphene therapy in women with anovulation.

Authors:  I Gerhard; B Runnebaum
Journal:  Arch Gynecol       Date:  1979

Review 5.  Drug-induced changes in prolactin secretion. Clinical implications.

Authors:  K Hell; H Wernze
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

6.  Cellular effects of tamoxifen in primary breast cancer.

Authors:  J F Robertson; I O Ellis; R I Nicholson; A Robins; J Bell; R W Blamey
Journal:  Breast Cancer Res Treat       Date:  1992-01       Impact factor: 4.872

7.  The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1988-07       Impact factor: 4.872

Review 8.  Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

9.  Effects of estradiol and some antiestrogens (clomiphene, tamoxifen, and hydroxytamoxifen) on luteinizing hormone secretion by rat pituitary cells in culture.

Authors:  G Emons; O Ortmann; S Thiessen; R Knuppen
Journal:  Arch Gynecol       Date:  1986

Review 10.  Tamoxifen reduces serum insulin-like growth factor I (IGF-I).

Authors:  M N Pollak; H T Huynh; S P Lefebvre
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.